NSE ScannerOpen the scanner

Pharmaceuticals · Pharmaceuticals: Major · NSE: AMBALALSA · data 2026-10-30

Ambalal Sarabhai Enterprises Limited

₹34.99-0.91% on 30 OctHealth: Average 6.1/10
Apr 2026Low ₹30.89 · High ₹48.27+7.8%

In plain words

Price: 30.0% below its 52-week high of ₹49.98.

Delivery: 53.5% of traded shares were kept for delivery over the last 10 sessions, against 62.5% over the last 60.

A description of the data, not a recommendation.

Open full analysis — chart, results, balance sheet, red flags →

Key figures

Price
₹34.99
Market cap
₹268 cr
P/E
19.8
P/B
—
ROE
11.9%
ROCE
9.4%
Debt / equity
0.36
Dividend yield
0.00%
1-year return
8.3%
52-week high
₹49.98
52-week low
₹30.15
Operating margin
5.1%

Growth

Revenue (last 12 months)₹206 cr
Net profit (last 12 months)₹14 cr
Sales growth, 3 years (yearly)5.9%
Profit growth, 3 years (yearly)15.9%

Smart-money activity

5/100 · Weak over the last ~60 sessions, data 2026-10-30

A description of recorded activity (delivery, deals, insider buys, fund holding, pledges), not a recommendation. Today's most active stocks.

Common questions

Is Ambalal Sarabhai Enterprises Limited debt-free?

Its latest reported debt-to-equity ratio is 0.36.

What is Ambalal Sarabhai Enterprises Limited's P/E ratio?

About 19.8, based on the last 12 months' earnings and a price of ₹34.99 (data 2026-10-30).

What is the 52-week high and low of Ambalal Sarabhai Enterprises Limited?

The 52-week high is ₹49.98 and the 52-week low is ₹30.15.

Similar companies

Jenburkt Pharmaceuticals Ltd (JENBURPH) · Medicamen Biotech Limited (MEDICAMEQ) · Aarey Drugs & Pharmaceuticals Ltd. (AAREYDRUGS) · Accretion Pharmaceuticals Ltd. (ACCPL) · Nectar Lifesciences Ltd. (NECLIFE)

The full analysis has the price chart, every quarterly result with YoY/QoQ growth, the balance sheet and cash flow with an accounting red-flag check, shareholding quarter by quarter with big investors, news, filings and bulk/block deals.

Open AMBALALSA in NSE Scanner →
Share on WhatsAppShare on Telegram